🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
This study is evaluating the safety and immunogenicity of GSK Biologicals' ...
Status
Completed
Location
GSK Investigational Site
Start Date
2004-08-01
Trial ID
NCT00129129
This study is evaluating the safety and immunogenicity of Hib-MenCY-TT vacc...
Status
Completed
Location
GSK Investigational Site
Start Date
2005-04-11
Trial ID
NCT00134719
Treatments Being Tested
The primary phase of this study is evaluating the safety of Hib-MenCY-TT va...
Status
Completed
Location
GSK Investigational Site
Start Date
2006-09
Trial ID
NCT00345579
The purpose of the study is to characterize the immunogenicity \& safety of...
Status
Completed
Location
GSK Investigational Site
Start Date
2008-02-13
Trial ID
NCT00614614
This study evaluates the immunogenicity and consistency of 3 Hib-MenCY-TT v...
Status
Completed
Location
GSK Investigational Site
Start Date
2006-02-22
Trial ID
NCT00289783
The purpose of this study is to evaluate the safety, reactogenicity and imm...
Status
Completed
Location
GSK Investigational Site
Start Date
2014-02-01
Trial ID
NCT01978093
Treatments Being Tested
This study is evaluating antibody persistence at 1, 3 \& 5 years post-fourt...
Status
Completed
Location
GSK Investigational Site
Start Date
2006-09
Trial ID
NCT00359983
Treatments Being Tested
This study evaluated the safety and immunogenicity of 3 formulations of Hib...
Status
Completed
Location
GSK Investigational Site
Start Date
2003-03-01
Trial ID
NCT00127855
This study evaluated the safety and immunogenicity of 3 formulations of Hib...
Status
Completed
Location
GSK Investigational Site
Start Date
2003-03-01
Trial ID
NCT00129116
Treatments Being Tested
The booster phase of the study will evaluate the safety of Hib-MenCY-TT vac...
Status
Completed
Location
GSK Investigational Site
Start Date
2007-07
Trial ID
NCT00345683